Evidence mapPaperPMID 39770936Full record

ReviewNutrients2024

Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives.

Alessandro Medoro, Sergio Davinelli, Federica Fogacci, Stefania Alfieri, Domenico Tiso, Arrigo F G Cicero, Giovanni Scapagnini

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessandro MedoroDepartment of Medicine and Health Sciences "V.Tiberio", University of Molise, 86100 Campobasso, Italy.ORCID 0000-0002-6285-607X
Sergio DavinelliDepartment of Medicine and Health Sciences "V.Tiberio", University of Molise, 86100 Campobasso, Italy.ORCID 0000-0003-2578-7199
Federica FogacciHypertension and Cardiovascular Risk Research Unit, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy.ORCID 0000-0001-7853-0042
Stefania AlfieriCentro Mediprò, 40068 San Lazzaro di Savena, Italy.
Domenico TisoClinical Nutrition, "Villa Maria" Hospital, 47921 Rimini, Italy.ORCID 0000-0001-5001-3668
Arrigo F G CiceroHypertension and Cardiovascular Risk Research Unit, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy.ORCID 0000-0002-4367-3884
Giovanni ScapagniniDepartment of Medicine and Health Sciences "V.Tiberio", University of Molise, 86100 Campobasso, Italy.ORCID 0000-0003-1592-5586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Menopause leads to a decline in estrogen levels, resulting in significant metabolic alterations that increase the risk of developing metabolic syndrome-a cluster of conditions including central obesity, insulin resistance, dyslipidemia, and hypertension. Traditional interventions such as hormone replacement therapy carry potential adverse effects, and lifestyle modifications alone may not suffice for all women. This review explores the potential role of palmitoylethanolamide (PEA), an endogenous fatty acid amide, in managing metabolic syndrome during the postmenopausal period. PEA primarily acts by activating peroxisome proliferator-activated receptor-alpha (PPAR-α), influencing lipid metabolism, energy homeostasis, and inflammation. Evidence indicates that PEA may promote the browning of white adipocytes, enhancing energy expenditure and reducing adiposity. It also improves lipid profiles by boosting fatty acid oxidation and decreasing lipid synthesis, potentially lowering low-density lipoprotein cholesterol and triglyceride levels while increasing high-density lipoprotein cholesterol. Additionally, the anti-inflammatory properties of PEA enhance insulin sensitivity by reducing pro-inflammatory cytokines that interfere with insulin signaling. PEA may aid in weight management by influencing appetite regulation and improving leptin sensitivity. Furthermore, its neuroprotective effects may address the mood disturbances and cognitive decline associated with menopause. Given these multifaceted biological activities and a favorable safety profile, PEA may represent a promising non-pharmacological supplement for managing metabolic syndrome in postmenopausal women. However, further large-scale clinical studies are necessary to establish its efficacy, optimal dosing, and long-term safety. If validated, PEA could become an integral part of strategies to improve metabolic and neuropsychological health outcomes in this population.

Indexed as

AmidesEthanolaminesMetabolic SyndromePalmitic AcidsPostmenopauseEnergy MetabolismFemaleHumansInsulin ResistanceLipid MetabolismAmidesEthanolaminespalmidrolPalmitic Acidsappetite regulationinsulin resistancelifestyle interventionsmenopausemetabolic syndromepalmitoylethanolamidePPAR-αweight management

Identifiers

PMID39770936
PMCPMC11677032

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.